Article

Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years

2024-03-13

Abstract excerpt

<h4>Background: </h4> Long-term data on ustekinumab in real-life Crohn’s disease patients are still missing, though randomized controlled trials demonstrated it as a favorable therapeutic option. <h4>Aims: </h4>: We aimed to evaluate ustekinumab's clinical efficacy, drug sustainability, and safety in a prospective, nationwide, multicenter Crohn’s disease patient cohort with a three-year follow-up. <h4>Methods: <...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4e3b1e70-3519-5e09-99d5-6f348a43d8c8
DOI: 10.21203/rs.3.rs-3952188/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three yearsDOI 10.21203/rs.3.rs-3952188/v1Read

Comparative Effectiveness and Safety of Ustekinumab versus Anti–TNF Therapy in Crohn Disease: A Systematic ReviewSemantic proximity Read

Evolving Treatment Algorithms in Crohn's Disease.Semantic proximity Read

Patients With Stricturing or Penetrating Crohn's Disease Phenotypes Report High Disease Burden and Treatment Needs.Semantic proximity Read

Prevalence, Incidence, Mortality and Trends in Treatment of Inflammatory Bowel Disease in Catalonia Between 2017 and 2023. An Epidemiological UpdateSemantic proximity Read

[Association of Toll-like receptor 5 gene polymorphism with the clinical efficacy of ustekinumab in patients with Crohn's disease].Semantic proximity Read

A Comparison of the Randomized Clinical Trial Efficacy and Real-World Effectiveness of Tofacitinib for the Treatment of Inflammatory Bowel Disease: A Cohort StudySemantic proximity Read

Variables associated with progression of moderate-to-severe Crohn's disease.Semantic proximity Read

Characterization of Inflammatory Bowel Disease in the Elderly According to Age of OnsetSemantic proximity Read

A longitudinal single-cell therapeutic atlas of anti-tumour necrosis factor treatment in inflammatory bowel diseaseSemantic proximity Read

Adverse reactions associated with the use of ustekinumab in Crohn's disease treatment：an analysis based on the FAERS databaseSemantic proximity Read

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.Semantic proximity Read

COVID-19 Vaccine Hesitancy Among Patients with Inflammatory Bowel Disease on Biologic Therapies; A cross-sectional studySemantic proximity Read